Low-dose Interferon-gamma-producing Human Neuroblastoma Cells Show Reduced Proliferation and Delayed Tumorigenicity
Overview
Authors
Affiliations
Interferon-gamma (IFN-gamma) directs T helper-1 cell differentiation and mediates antitumour effects in preclinical models. However, high-dose IFN-gamma is toxic in vivo, and IFN-gamma-transfected neuroblastoma (NB) cells secreting high amounts of the cytokine may be lost due to cell apoptosis or differentiation. Two human NB cell lines (ACN and SK-N-BE2(c)) differing as to genetic and phenotypic features were transfected with the human IFN-gamma gene and selected on the grounds of the low concentrations of IFN-gamma produced. In both IFN-gamma-transfected cell lines, autocrine and paracrine activation of IFN-gamma-mediated pathways occurred, leading to markedly reduced proliferation rate, to increased expression of surface HLA and CD40 molecules and of functional TNF binding sites. ACN/IFN-gamma cells showed a significantly delayed tumorigenicity in nude mice as compared to parental cells. ACN/IFN-gamma tumours were smaller, with extensive necrotic area as a result of a damaged and defective microvascular network. In addition, a significant reduction in the proliferation index was observed. This is the first demonstration that IFN-gamma inhibits in vivo proliferation of NB cell by acting on the tumour cell itself. This effect adds to the immunoregulatory and antiangiogenic activities operated by IFN-gamma in syngeneic tumour-bearing hosts.
Zeki J, Yavuz B, Wood L, Shimada H, Kaplan D, Chiu B Pediatr Surg Int. 2023; 39(1):241.
PMID: 37500800 DOI: 10.1007/s00383-023-05523-w.
Birley K, Leboreiro-Babe C, Rota E, Buschhaus M, Gavriil A, Vitali A Mol Ther Oncolytics. 2022; 26:429-443.
PMID: 36159778 PMC: 9467911. DOI: 10.1016/j.omto.2022.08.008.
Berge M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre J Am J Pathol. 2010; 177(6):3192-201.
PMID: 20971743 PMC: 2993283. DOI: 10.2353/ajpath.2010.100157.
Croce M, Meazza R, Orengo A, Fabbi M, Borghi M, Ribatti D Cancer Immunol Immunother. 2008; 57(11):1625-34.
PMID: 18324400 PMC: 11030971. DOI: 10.1007/s00262-008-0496-3.
Ribatti D, Nico B, Pezzolo A, Vacca A, Meazza R, Cinti R Br J Cancer. 2006; 94(12):1845-52.
PMID: 16721359 PMC: 2361332. DOI: 10.1038/sj.bjc.6603186.